EPS for Intellia Therapeutics Inc. (NTLA) Expected At $-0.43; CREDNOLOGY HOLDING (COHO) Shorts Decreased By 32.94%

February 16, 2018 - By Adrian Erickson

CREDNOLOGY HOLDING (OTCMKTS:COHO) had a decrease of 32.94% in short interest. COHO’s SI was 56,600 shares in February as released by FINRA. Its down 32.94% from 84,400 shares previously. The stock increased 50.00% or $0.0001 during the last trading session, reaching $0.0003. About 530,000 shares traded. Crednology Holding Corporation (OTCMKTS:COHO) has 0.00% since February 16, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts expect Intellia Therapeutics Inc. (NASDAQ:NTLA) to report $-0.43 EPS on March, 13.They anticipate $0.12 EPS change or 38.71% from last quarter’s $-0.31 EPS. After having $-0.44 EPS previously, Intellia Therapeutics Inc.’s analysts see -2.27% EPS growth. The stock increased 2.19% or $0.56 during the last trading session, reaching $26.16. About 253,034 shares traded. Intellia Therapeutics Inc. (NASDAQ:NTLA) has declined 46.16% since February 16, 2017 and is downtrending. It has underperformed by 62.86% the S&P500.

Among 4 analysts covering Intellia Therapeutics (NASDAQ:NTLA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intellia Therapeutics had 5 analyst reports since May 31, 2016 according to SRatingsIntel. The rating was initiated by Credit Suisse with “Outperform” on Tuesday, May 31. The stock of Intellia Therapeutics Inc. (NASDAQ:NTLA) earned “Outperform” rating by Leerink Swann on Friday, August 5. Wedbush initiated the shares of NTLA in report on Tuesday, May 31 with “Outperform” rating. The firm has “Buy” rating given on Friday, August 5 by Jefferies. On Tuesday, May 31 the stock rating was initiated by Jefferies with “Hold”.

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company has market cap of $1.11 billion. The firm develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. It currently has negative earnings. The Company’s ex vivo pipeline includes proprietary and partnered programs focuses on chimeric antigen receptor T cells and hematopoietic stem cells.

Crednology Holding Corporation provides credit management and credit education in the United States. The company has market cap of $586,152. The company, through its subsidiary, CreditDNA, Inc., offers personal credit and financial management programs. It currently has negative earnings. It also informs about the importance of establishment and maintenance of a healthy financial and credit lifestyle.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>